Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Treasury Shares (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Treasury Shares for 11 consecutive years, with $3.2 million as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares rose 81.56% year-over-year to $3.2 million; the TTM value through Mar 2026 reached $3.2 million, up 81.56%, while the annual FY2025 figure was $1.5 million, 79.06% up from the prior year.
  • Treasury Shares hit $3.2 million in Q1 2026 for Wave Life Sciences, up from $1.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.2 million in Q1 2026 and bottomed at $614449.0 in Q1 2023.
  • Average Treasury Shares over 5 years is $1.2 million, with a median of $832043.0 recorded in 2024.
  • Year-over-year, Treasury Shares tumbled 50.18% in 2022 and then surged 181.15% in 2025.
  • Wave Life Sciences' Treasury Shares stood at $934342.0 in 2022, then plummeted by 31.76% to $637557.0 in 2023, then soared by 30.5% to $832043.0 in 2024, then soared by 79.06% to $1.5 million in 2025, then soared by 117.67% to $3.2 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $3.2 million, $1.5 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.